Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Optimizing First-Line Therapy in mCRC

January 29th 2021

Axel Grothey, MD, and John Marshall, MD, discuss strategies for optimizing first-line treatment in metastatic colorectal cancer and the role of adjuvant therapy.

Tislelizumab Prolongs Survival in Advanced, Unresectable, or Metastatic ESCC

January 28th 2021

January 28, 2021 - The anti–PD-1 antibody tislelizumab was found to significantly improve overall survival compared with investigator’s choice of chemotherapy in the treatment of patients with advanced, unresectable, or metastatic esophageal squamous cell carcinoma.

Dr. Marshall on the Emergence of Novel HER2-Targeted Agents in CRC

January 28th 2021

John L. Marshall, MD, discusses the emergence of novel HER2-targeted therapies for patients with colorectal cancer.

Dr. Mody on the Unique Delivery Approach for Y-90 in HCC

January 28th 2021

Kabir Mody, MD, discusses the unique approach used to deliver Y-90 glass microspheres to patients with unresectable hepatocellular carcinoma.

Dr. He on the Results of the LEGACY Study Examining Y-90 in HCC

January 27th 2021

Ruth Aiwu He, MD, PhD, discusses the results of the LEGACY study in patients with hepatocellular carcinoma.

FDA Grants Chemotherapeutic Uttroside-B Orphan Drug Designation for HCC

January 27th 2021

January 27, 2021 - The FDA has granted an orphan drug designation to the small molecule chemotherapeutic uttroside-B for use as a treatment in patients with hepatocellular carcinoma.

Onvansertib Plus FOLFIRI/Bevacizumab Shows Preliminary Efficacy, Tolerability in Second-Line mCRC

January 27th 2021

January 27, 2021 - The combination of the polo-like kinase 1 inhibitor, onvansertib, with FOLFIRI and bevacizumab was found to have preliminary activity and favorable tolerability when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.

Perioperative Chemotherapy Fails to Show OS Benefit in Resectable PDAC

January 27th 2021

January 27, 2021 - Perioperative chemotherapy did not improve overall survival in patients with resectable pancreatic ductal adenocarcinoma when compared with historical data from adjuvant trials.

Dr. Raghav on Sequencing Therapies for Resectable Versus Unresectable CRC

January 26th 2021

Kanwal Raghav, MBBS, MD, discusses his approach to sequencing therapies for patients with resectable and unresectable colorectal cancer.

Postoperative MRD Positivity Linked With Reduced RFS in CRC

January 26th 2021

January 26, 2021 — Patients with colorectal cancer who had molecular residual disease positivity immediately after surgery were found to have a high risk of disease recurrence and longitudinal monitoring increased the predictive power of circulating tumor DNA.

Experts Provide Real-World Advice for Molecular Testing in Gastrointestinal Malignancies

January 25th 2021

Johanna C. Bendell, MD, moderates a peer exchange with fellow experts to discuss differences in germline and somatic BRCA mutations in pancreatic cancer, the role of molecular testing in hepatocellular carcinoma, and treatment options for patients with BRAF-mutant, microsatellite instability–high colorectal cancer.

Big Data Tool Finds Variations in Treatment and Costs Across 3 Cancer Types

January 25th 2021

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.

Dr. Ciombor on the FDA Approval of Trastuzumab Deruxtecan in HER2+ Metastatic Gastric Cancer

January 22nd 2021

Kristen K. Ciombor, MD, MSCI, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric cancer.

Atezolizumab/Bevacizumab Is Favored for Further Study in HCC

January 22nd 2021

Joseph Kim, MD, discusses the multidisciplinary management of patients with HCC.

First-Line Options in mCRC

January 22nd 2021

Axel Grothey, MD, and John Marshall, MD, discuss first-line treatment options in patients with metastatic colorectal cancer.

Treatment Considerations in mCRC

January 22nd 2021

Axel Grothey, MD, discusses factors that influence treatment selection in patients with mCRC.

Personalized Y-90 Radiation Therapy Outperforms Standard Dosing in Advanced HCC

January 21st 2021

Beau Toskich, MD, discusses key results that demonstrate the benefit of personalized dosimetry, and offered advice to fellow clinicians as the field moves toward adopting this radiotherapeutic modality.

FDA Grants Priority Review to Adjuvant Nivolumab for Resected Esophageal or GEJ Cancer

January 20th 2021

The FDA has granted priority review to a supplemental biologics license application for nivolumab for use as an adjuvant treatment for patients with resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation treatment.

FDA Grants Priority Review to Nivolumab/Chemo for Frontline Metastatic Gastric, GEJ, and Esophageal Cancer

January 20th 2021

January 20, 2021 - The FDA has granted a priority review to a supplemental biologics license application for nivolumab in combination with a fluoropyrimidine- and platinum-containing chemotherapy for use in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

High-Dose Y-90 Pushes the HCC Paradigm Toward Personalized, Multidisciplinary Care

January 20th 2021

Beau Toskich, MD, discusses the potential of TheraSphere as a therapy in hepatocellular carcinoma, the importance of utilizing a multidisciplinary approach among novel radiation oncology agents, and his hope for a future prospective clinical trial evaluating Y-90.